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Abstract: Strongyloidiasis is a common neglected tropical disease in tropical and sub-tropical
climatic zones. At the worldwide level, there is high uncertainty about the strongyloidiasis burden.
This uncertainty represents an important knowledge gap since it affects the planning of interventions
to reduce the burden of strongyloidiasis in endemic countries. This study aimed to estimate the
global strongyloidiasis prevalence. A literature review was performed to obtain prevalence data
from endemic countries at a worldwide level from 1990 to 2016. For each study, the true population
prevalence was calculated by accounting for the specificity and the sensitivity of testing and age
of tested individuals. Prediction of strongyloidiasis prevalence for each country was performed
using a spatiotemporal statistical modeling approach. The country prevalence obtained from the
model was used to estimate the number of infected people per country. We estimate the global
prevalence of strongyloidiasis in 2017 to be 8.1% (95% CI: 4.2–12.4%), corresponding to 613.9 (95% CI:
313.1–910.1) million people infected. The South-East Asia, African, and Western Pacific Regions
accounted for 76.1% of the global infections. Our results could be used to identify those countries in
which strongyloidiasis prevalence is highest and where mass drug administration (MDA) should be
deployed for its prevention and control.
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1. Introduction
Strongyloidiasis is the infection caused by the soil-transmitted helminth (STH) Strongyloides
stercoralis. Its global prevalence was previously estimated at 30–100 million infected people [1],
but these estimates were subsequently questioned in light of diagnostic issues that characterized the
few studies available at that time [2]. Moreover, neither the source nor the methods which formed the
basis for these estimates were reported in the paper. Indeed, the diagnostic methods commonly used in
the field for other STHs, such as Kato–Katz and direct smear examination, have a very low sensitivity
for S. stercoralis [3]. The Baermann method and Koga agar plate culture (APC) have a higher sensitivity
than stool microcopy, but still miss a large proportion of infections [3]; polymerase chain reaction (PCR)
is highly specific, but not more sensitive than the Baermann method and APC [4]. Serology is the most
sensitive method, although false positive results are possible, due to cross-reactions and long-term
persistence of antibodies [3]. Overall, none of the available diagnostic tests can be considered the
gold standard for the diagnosis of strongyloidiasis. Recently, a paper estimated the prevalence of
strongyloidiasis as a ratio to hookworm, in order to partly overcome the diagnostic issue [5].
The morbidity caused by S. stercoralis is not well defined compared to other STHs. A systematic
review evaluated the clinical burden caused by strongyloidiasis and reported that urticaria (reported
by 33% of infected individuals in the included studies), abdominal pain (62%), and diarrhea (50%)
might be frequently affecting people with strongyloidiasis [6]. Although the results of the review
were limited by the paucity of studies focusing on this topic, the clinical relevance of S. stercoralis
infection cannot be disregarded, because in immunosuppressed individuals it can lead to a syndrome
(hyperinfection/dissemination) that is invariably fatal if not promptly and properly cured and is often
fatal despite treatment [7]. Ivermectin (IVM) is the drug of choice for the treatment of S. stercoralis
infection [7], and it has been recently included in the WHO list of essential medicines for this purpose [8].
Unfortunately, IVM is often not easily available outside specific donation programs aimed at the
elimination of lymphatic filariasis (LF) and onchocerciasis.
Currently, no specific strategies for the control of S. stercoralis infection have been implemented in
endemic areas. This is mostly due to the knowledge gap regarding the global prevalence of the disease
and the difficult access to quality-assured and affordable IVM.
In this work, we aimed to estimate the prevalence of strongyloidiasis at a global and country level,
using a spatiotemporal statistical modeling approach.
2. Results
2.1. Review of the Literature
The flow of the literature review is described in Figure 1. The review of the literature identified
146 articles (Supplementary File S1) with data on the prevalence of strongyloidiasis from 43 countries
(Figure 2). Brazil and Thailand were the countries with the highest number of studies. Twenty studies
used either the Baermann method or stool culture (including agar plate, Harada Mori or any other
cultural method) as diagnostic methods; a combination of diagnostic tests including Baermann method
and/or stool culture was used in 22 studies. PCR was used in 7 studies, and a further 2 studies used it
in combination with other tests. Serology was used in 16 studies, and a further 3 studies used serology
in combination with other tests. The remaining studies used less sensitive diagnostic methods (mostly
Kato–Katz and single/multiple direct smears). The prevalence reported was adjusted considering the
diagnostic test used, as described above in the Methods section.
2.2. Global and Regional (WHO) Prevalence According to the Model
The best model describing strongyloidiasis prevalence included GDP, percentage of rural
population, territory roughness, sanitation, annual mean temperature, and annual precipitation:
STG-PR = GDP + RURAL + RUG + SANIT + TEMP + RAIN + REGIONRND (1)
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This model was used to estimate strongyloidiasis prevalence for each country at the worldwide
level with a 95% confidence interval (95% CI).
Strongyloidiasis prevalence and number of infected people are reported at the world and regional
levels in Table 1 and Figure 3.
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Table 1. Global and regional S. stercoralis prevalence (STG-PR), the number of infected 
individuals. 
WHO REGION STG-PR (95% CI) POPULATION INFECTED (95% CI) [MILLION] 
AFR 10.3% (5.3–15.3) 108.1 (55.1–160.9) 
AMR 6.9% (3.5–10.2) 69.8 (35.5–103.9) 
EMR 5.8% (2.9–8.6) 39.4 (20.1–58.8) 
EUR 2.8% (1.4–4.1) 26.1 (13.3–38.8) 
SEAR 12.1% (6.1–17.9) 237.3 (129.9–353.3) 
WPR 7.13% (3.6–10.6) 133.2 (68.1–198.4) 
World 8.1% (4.2–12.4%) 613.9 (313.1–910.1) 
AFR: African Region; AMR: American Region; EMR: Eastern Mediterranean Region; EUR: European 
Region; SEAR; South-East Asia Region; WPR: Western Pacific Region. 
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Figure 3. Estimated strongyloidiasis prevalence (STG-PR) for 2017, as predicted by the best
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Table 1. Global and regional S. stercoralis prevalence (STG-PR), the number of infected individuals.
WHO Region STG-PR (95% CI) Population Infected (95% CI) [Million]
AFR 10.3% (5.3–15.3) 108.1 (55.1–160.9)
AMR 6.9% (3.5–10.2) 69.8 (35.5–103.9)
EMR 5.8% (2.9–8.6) 39.4 (20.1–58.8)
EUR 2.8% (1.4–4.1) 26.1 (13.3–38.8)
SEAR 12.1% (6.1–17.9) 237.3 (129.9–353.3)
WPR 7.13% (3.6–10.6) 133.2 (68.1–198.4)
World 8.1% (4.2–12.4%) 613.9 (313.1–910.1)
AFR: African Region; AMR: American Region; EMR: Eastern Mediterranean Region; EUR: European Region;
SEAR: South-East Asia Region; WPR: Western Pacific Region.
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In 2017, the estimated strongyloidiasis prevalence was 8.1% (95% CI: 4.2%–12.4%),
which corresponds to 613.9 (95% CI: 313.1–910.1) million people infected with Strongyloides.
Referring to the WHO regions, the highest number of infected people live in the South-East Asia Region
(SEAR) estimated at 237.3 (95% CI: 129.9–353.3) million, followed by Western Pacific Region (WPR)
with 133.2 (95% CI: 68.1–198.4) million, and African Region (AFR) with 108.1 (95% CI: 55.1–160.9)
million; combined this represents 76.1% of the total infected population worldwide (Table 1).
At the regional level, high S. stercoralis prevalence was estimated for countries in AFR
(10.3%; 95% CI: 5.3–15.3%), for the Americas Region (AMR) (6.9%; 95% CI: 3.5–10.2%), and SEAR
(12.1%; 95% C.I.: 6.1–17.9%). In the AMR, countries in Central America and the northern part of South
America had the highest prevalence (Figure 3), particularly Panama (15.7%; 95% CI: 8–23.4%), Costa Rica
(15.7%; 95% CI: 8–23.4%), and Colombia (18.4%; 95% CI: 9.4–27.4%). S. stercoralis prevalence in AFR was
estimated to be high in sub-Saharan countries, with prevalence in West Africa higher compared with the
rest of the AFR countries and Sierra Leone (17%; 95% CI: 8.7–25.3%), Liberia (16%; 95% CI: 8.4–24.6%),
and Sao Tome and Principe (20.7%; 95% CI: 10.6–30.8%) having particularly high estimated prevalence.
All countries in the SEAR had high levels of strongyloidiasis prevalence, with the highest prevalence
estimated for Myanmar (19.2%; 95% CI: 9.8–28.6%). Low prevalence of infection (<0.1%) was estimated
for high-income countries in temperate zones, with countries at the northern latitudes having the
lowest prevalence. Prevalence estimates at country level are reported in Table S1.
3. Discussion
Different to the previous review on the global prevalence [9], here we provide new estimates of
S. stercoralis prevalence at a global level. Our results suggest that, similar to other STHs, a large number
of people are infected by S. stercoralis worldwide and they are mostly distributed in sub-Saharan Africa,
Latin America and East Asia [10]. The global prevalence resulting from our modeling is ten times higher
than previous estimates, ranging between 30 to 100 million people [1]. Although these estimates are
regularly cited by articles on S. stercoralis, we were unable to find any evidence base for these estimates as
well as for previous (assessing the prevalence at 3 to 30 million cases [1,11]) (under)estimation. This may
be the main reason why S. stercoralis infection has lagged behind other STHs in being addressed
in countries’ STH control programming. Recently, a systematic review and meta-analysis [12] on
schistosomiasis and S. stercoralis prevalence in migrants from endemic countries to non-/low-endemic
countries (defined as the United States, Canada, Australia, New Zealand, Western Europe, and Israel)
reported similar prevalence figures to ours for the migrants’ main geographic areas of origin.
S. stercoralis infection affects an important proportion of the world population and this calls for
action. Not surprisingly, almost all cases of the severe, usually fatal form of the disease are reported,
precisely, in non-endemic countries, with very few cases reported from the highly-endemic geographic
areas [13]. This means that most of the deaths caused by this parasite are simply undetected. Moreover,
besides the disseminated disease that is caused by immune suppression in chronically infected patients,
the clinical burden of the chronic, uncomplicated S. stercoralis infection is still poorly known [6,14],
reflecting the paucity of studies and the general lack of funding for research on this parasite.
The number of studies reporting data on the prevalence of S. stercoralis infection is still scarce
and sparse in time and space. This paucity of data with very few country-level surveys is the main
limitation in our study. Furthermore, many studies included in our review still relied on diagnostic tests
with a low sensitivity which would have resulted in an underestimation of the prevalence. Adjustment
for test accuracy and a robust model that could fill the gap in data in many areas were necessary.
Because we did not have enough data to have time series of testing results from the same location for a
long period, we were not able to account in our model for the effect of MDA based on IVM targeting
other parasites.
A consensus should be reached on priority research areas that could support operational
S. stercoralis prevention and control programming. If no action is taken a preventable disease will
keep on taking thousands if not hundreds of thousands of lives. Indeed, because S. stercoralis causes a
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long-lasting infection, the proportion of infections in adults is higher than in children. While IVM is
effective against S. stercoralis infection, a mass drug administration program only for S. stercoralis would
be difficult to implement due to cost constraints. Ad hoc cost–benefit analyses might help to identify
the best strategies to tackle S. stercoralis operationally, either on its own or in combination/integrated
with other worm infections.
At least in a preliminary phase, prior to operational activities being implemented based on
prevalence data from studies conducted one or two decades ago, it would be important to conduct
surveys to estimate the prevalence of S. stercoralis in specific (e.g., high burden) areas and confirm
modeling outputs presented here. There is an urgent need for guidelines indicating the optimal
diagnostic methods for such surveys to allow for homogeneous and reliable estimates of prevalence.
4. Materials and Methods
Prevalence data was modeled based on data retrieved from a literature review and a number of
sources that provide data on key predictors of S. stercoralis prevalence. The review of the literature was
performed in May 2017 in three databases (PubMed, WHOLIS, ISI Web of Science), using the MeSH
terms “Strongyloides” and “Strongyloidiasis”, with no date of publication or language restrictions.
The methods for the literature search are described in Supplementary File S2.
Country population data were obtained from the World Bank website [15], including total
population, percentage of the population living in rural areas, and the fraction of the population by
age, up to age 14 and older than 14 years. Additional data on the gross domestic product (GDP) per
capita and percentage of GDP spent on health (for all sectors and the public sector) were collected from
the World Bank website. Strongyloidiasis prevalence is also linked with the level of sanitation in a
country [16]. To include this information in our analyses, we accessed the percentage of the population
with access to a proper latrine from the UNICEF website [17].
Environmental factors also affect strongyloidiasis prevalence [18]. To account for environmental
characteristics of each country, we included in our analyses the terrain ruggedness index [19] and land
use characteristics (i.e., the percentage of the total country area that is desert, agricultural, and forest).
These data were collected from the FAO website and Nunn and Puga [20]. S. stercoralis larvae living in
soil have a high chance of surviving in humid and warm weather [21]. To account for country climate
suitability for strongyloidiasis prevalence in our analyses, we included country data on annual average
temperature and total annual rainfall from the World Bank website.
All tabular data were imported into a database based on SQLite [22]. Geographical data were
processed using QGIS [23], and statistical analyses performed using the R language [24] through the
RStudio interface [25]. All the analyses were performed using free and open-source software installed
on a Linux Mint 18 platform.
4.1. Estimation of Country Prevalence
To estimate the final country prevalence of strongyloidiasis, we had to adjust the data reported in
each survey to the accuracy of the diagnostic test used and the age of tested individuals. The reported
strongyloidiasis prevalence extracted through the literature review was adjusted using the specificity
and sensitivity of each diagnostic test, reported by studies comparing the different diagnostic tests [25]
and systematic reviews [3,4,26]. In particular, the following ranges of sensitivity were considered:
direct stool examination/Kato–Katz: 5–21% [26]; formol ethyl-acetate concentration technique
(FECT): 9–48% [4,26]; Baermann method and APC: 45–89% [26]; PCR: 62–72% [4]; IFAT: 81–98% [25];
ELISA crude antigen: 73–100 [25]; NIE-ELISA: 71–84% [25]; LIPS: 84–97% [25]. We performed the
accuracy adjustment using the methods described in the scientific literature [27]. This correction used
the direct relation between prevalence, sensitivity and specificity (details in Supplementary File S3).
For each country, a final weighted mean of the adjusted prevalence by the sample size of each study
was computed. After adjusting by test accuracy, we needed to calculate the all-age strongyloidiasis
prevalence at the country level. Many studies did not sample all age groups but focused on particular
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ones. In order to estimate strongyloidiasis prevalence for the entire population of countries without an
all-age prevalence, we separately estimated prevalence for children and adults. We considered two
age groups: children < 15 years of age and individuals ≥ 15 years of age. We compared the infection
prevalence of these two age groups (Figure 4) to compute the groups’ prevalence ratio. The ratio was
obtained by calculating the mean of the ratio of the prevalence of the two age groups using those
studies in which both age groups were sampled. The ratio was used as an adjusting factor to obtain
the unknown strongyloidiasis prevalence of one of the age groups based on the known prevalence of
the other age group. The prevalence of the two age groups was used to calculate the strongyloidiasis
prevalence of the entire country’s population. The calculation took into consideration the proportion
of the population belonging to the two age groups.
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4.2. Statistical Methods
A model approach was implemented to calculate the strongyloidiasis prevalence at the worldwide
level for the year 2017. A generalized linear mixed model (GLMM) was used to investigate the
relationship of strongyloidiasis prevalence with economic and environmental factors [28]. The model
was built using variables that could hav an effect n strongyloidia is prevalence levels in a country:
STG-PR = GDP + GDPHealth + EDU + RURAL + CROP + FOREST + RUG + SANIT
+ TEMP + RAIN + REGIONRND
(2)
where GDP is per capita gross domestic product, GDPHealth is the percentage of GDP allocated
to health expenditure, EDU is the percentage of the population who attended primary education,
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RURAL is the percentage of the population living in a rural setting, CROP is the percentage of the
country’s land allocated for agriculture, FOREST is the percentage of the country’s land covered by
forest, RUG is the ruggedness index of the country, SANIT is the percentage of the population with
access to a proper latrine, TEMP is the mean annual temperature, RAIN is the total annual rainfall,
and REGIONRND is the region as a random effect.
To determine the most important variable associated with strongyloidiasis prevalence, a model
selection approach was applied to identify which variable had the highest ability to predict
strongyloidiasis prevalence. A set of possible models were created, starting from the full model
formula and varying the included variables (Table S2). Model selection was performed using the
Akaike Information Criteria (AIC) of each model. The model with the lowest AIC was identified as the
best one and was used to predict strongyloidiasis prevalence for the year 2017 [29].
5. Conclusions
Global prevalence of S. stercoralis is probably higher than previously thought. Ad hoc surveys
should be carried out in areas where prevalence is estimated as high, prior to designing operational
programs to control S. stercoralis.
Supplementary Materials: The following are available online at http://www.mdpi.com/2076-0817/9/6/468/s1, File
S1: References of papers included in the analysis, File S2: Review protocol, File S3: Prevalence adjustment based
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